Leishen Energy Holding Co., Ltd. - Class A Ordinary Shares (LSE)

LONDON and PHILADELPHIA, April 14, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announces that the life sciences industry publication In Vivo, published by Citeline, has named its CEO Christina Coughlin MD, PhD as one of its 2026 Rising Leaders.

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

NEW YORK, April 13, 2026 (GLOBE NEWSWIRE) -- Alpha Financial Markets Consulting (“Alpha”), a leading global provider of specialist consulting services to the financial services industry, has entered into an agreement to acquire JPSB Group Limited (“JPSB”), a specialist SimCorp-focused technology consulting and implementation firm.

RIYADH, Saudi Arabia, April 13, 2026 (GLOBE NEWSWIRE) -- Leishen Energy Holding Co., Ltd. ("Leishen Energy" or the "Company") (NASDAQ: LSE), a leading provider of clean-energy equipment and integrated solutions for the oil and gas industry, today reaffirmed its long-term strategic commitment to the Middle East market, confirming that the development of its Saudi Arabia production facility, LSE Energy International, continues to advance as planned, notwithstanding ongoing regional conflicts.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California.

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics

Inclusion Comes Shortly After Completion of U.S. IPO

Revenue Growth Driving Group to Record EBITDA

Earnings accretive; expands UK advisory and economics capabilities

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma (“DLBCL”) in China. The first patient received the first dose on March 20, 2026.

WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- Public Policy Holding Company, Inc. ("PPHC" or "the Company") (Nasdaq: PPHC), a leading global provider of strategic communications services, today announced that TrailRunner International ("TrailRunner"), one of the Company's member firms, has named Alden Mitchell as President of TrailRunner Sports, its global sports advisory business.

LONDON and PHILADELPHIA, March 17, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding TAZVERIK® (tazemetostat), an oncology therapy licensed from Epizyme, Inc. (“Epizyme”), an Ipsen (“Ipsen”) company, in China. Epizyme is the Marketing Authorization Holder of TAZVERIK® in the Chinese mainland, for which HUTCHMED Limited (a subsidiary of the Company) acts as the domestic agent/licensee. Ipsen has informed HUTCHMED that it is voluntarily withdrawing TAZVERIK® in the US. As a result, steps have been taken to initiate the market withdrawal and product recall in China. Consequently, HUTCHMED Limited has initiated a withdrawal and product recall from the Chinese mainland, Hong Kong and Macau, and is discontinuing all active tazemetostat clinical trials. Existing patients should consult their treating physicians immediately to discuss their treatment options.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Mok Shu Kam, Tony has informed the Company that he would not seek re-election after retiring from the Board at the forthcoming annual general meeting of the Company to be held on May 12, 2026 (“AGM”). Professor Mok has served as an Independent Non-executive Director of the Company for more than eight years, approaching the nine-year cap on the tenure of independent non-executive directors under the Hong Kong Listing Rules. Consequently, he will cease to be an Independent Non-executive Director of the Company at the conclusion of the AGM. Upon his retirement, he will also step down from his roles as chairman and member of the board committees of the Company. 

WASHINGTON, March 05, 2026 (GLOBE NEWSWIRE) -- Public Policy Holding Company, Inc. (“PPHC” or “the Company”) (Nasdaq: PPHC) (AIM: PPHC), a leading global strategic communications provider offering a comprehensive range of advisory services in the areas of Government Relations, Public Affairs and Corporate Communications, today announced that it will release its fourth quarter and full year 2025 financial results on Monday, March 23, 2026, after market close.

— Geographic expansion driving ex-China sales growth; indication expansions driving China sales growth —

— Second clinical candidate from HUTCHMED’s next-generation ATTC platform —

Experimental data from FAP-Exd (AVA6103) demonstrates a more favorable profile compared to the marketed Antibody Drug Conjugate (ADC) Enhertu®

BEIJING, Feb. 15, 2026 (GLOBE NEWSWIRE) -- Leishen Energy Holding Co., Ltd. (“Leishen Energy,” the “Company”) (Nasdaq: LSE) announced its fiscal year 2025 financial results on January 30, 2026, reflecting a transition period: core operating performance weakened, but the Company strengthened its financial foundation through the IPO, reduced leverage, and improved liquidity. The Company’s cash position and low debt levels provide flexibility to address operational challenges, while continued improvements in asset quality help mitigate financial risks.

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

LONDON and PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has appointed Francis Wilson as its Chief Scientific Officer.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price

Cardiac dosing limit removed and path forward to dose selection identified